{"id":63227,"date":"2026-04-15T21:33:21","date_gmt":"2026-04-15T13:33:21","guid":{"rendered":"https:\/\/flcube.com\/?p=63227"},"modified":"2026-04-15T21:33:22","modified_gmt":"2026-04-15T13:33:22","slug":"lepu-medical-acquires-betagrin-rights-from-bio-thera-in-rmb-450-million-cardiovascular-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63227","title":{"rendered":"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal"},"content":{"rendered":"\n<p><strong>Lepu Medical Technology<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/300003:SHE\">SHE: 300003<\/a>), a leading Chinese provider of <strong>cardiovascular disease solutions<\/strong>, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company <strong>Bio-Thera Solutions Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688177:SHA\">SHA: 688177<\/a>) to acquire <strong>all rights, assets, and business<\/strong> related to <strong>Betagrin (batifiban)<\/strong>, a recently approved antiplatelet therapy for acute coronary syndrome.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Lepu Medical Technology (SHE: 300003)<\/td><\/tr><tr><td><strong>Licensor<\/strong><\/td><td>Bio-Thera Solutions Inc. (SHA: 688177)<\/td><\/tr><tr><td><strong>Upfront Payment<\/strong><\/td><td>RMB 450 million (USD 66 million)<\/td><\/tr><tr><td><strong>Milestone Structure<\/strong><\/td><td>Single-digit percentage of annual net sales<\/td><\/tr><tr><td><strong>Revenue Sharing Period<\/strong><\/td><td>Up to 10 years from commercial launch<\/td><\/tr><tr><td><strong>Asset Acquired<\/strong><\/td><td>Betagrin (batifiban) \u2013 all rights, assets, and business<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-regulatory-status\">Product Profile &amp; Regulatory Status<\/h2>\n\n\n\n<p><strong>Betagrin (batifiban)<\/strong> is a <strong>peptide-based \u03b23 integrin receptor inhibitor<\/strong> that received <strong>NMPA approval in June 2024<\/strong> for a specific high-risk cardiovascular indication:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication<\/strong>: Patients with <strong>acute coronary syndrome<\/strong> undergoing <strong>percutaneous coronary intervention<\/strong> (PCI), including coronary artery stent placement<\/li>\n\n\n\n<li><strong>Clinical Benefit<\/strong>: Reduces risk of critical PCI complications including:<\/li>\n\n\n\n<li>Acute occlusion<\/li>\n\n\n\n<li>In-stent thrombosis<\/li>\n\n\n\n<li>No-reflow phenomenon<\/li>\n\n\n\n<li>Slow-flow phenomenon<\/li>\n\n\n\n<li><strong>Mechanism<\/strong>: Selective inhibition of \u03b23 integrin receptors on platelets, preventing platelet aggregation during high-risk vascular procedures<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale\">Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Synergy<\/strong>: Acquisition aligns perfectly with Lepu&#8217;s core focus on cardiovascular disease solutions and interventional cardiology<\/li>\n\n\n\n<li><strong>Commercial Integration<\/strong>: Lepu&#8217;s established hospital distribution network and relationships with interventional cardiologists provide immediate commercial leverage<\/li>\n\n\n\n<li><strong>Market Opportunity<\/strong>: Addresses unmet needs in PCI procedures where current antiplatelet therapies may be insufficient to prevent acute complications<\/li>\n\n\n\n<li><strong>Vertical Integration<\/strong>: Combines Lepu&#8217;s medical device expertise with pharmaceutical solutions for comprehensive cardiovascular care<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-analysis\">Market Analysis<\/h2>\n\n\n\n<p>The <strong>acute coronary syndrome market<\/strong> in China represents significant growth potential due to rising cardiovascular disease prevalence and increasing adoption of advanced interventional procedures. Key competitive advantages include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Recent Approval<\/strong>: June 2024 NMPA approval positions Betagrin as a modern therapeutic option<\/li>\n\n\n\n<li><strong>Specific Indication<\/strong>: Targeted use in high-risk PCI procedures creates a focused commercial strategy<\/li>\n\n\n\n<li><strong>Safety Profile<\/strong>: Peptide-based mechanism may offer improved safety compared to traditional antiplatelet agents<\/li>\n\n\n\n<li><strong>Hospital Focus<\/strong>: Natural fit within Lepu&#8217;s existing hospital-centric commercial model<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<p>The deal structure provides attractive economics for both parties:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Bio-Thera<\/strong>: Receives substantial upfront payment while retaining long-term revenue participation<\/li>\n\n\n\n<li><strong>Lepu<\/strong>: Gains immediate access to an approved cardiovascular drug with established clinical utility and regulatory pathway<\/li>\n\n\n\n<li><strong>Revenue Potential<\/strong>: Single-digit royalty on net sales over 10 years creates sustainable long-term value creation<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-industry-outlook\">Industry Outlook<\/h2>\n\n\n\n<p>This transaction reflects the growing trend of <strong>strategic asset optimization<\/strong> among Chinese pharmaceutical companies, where specialized firms focus on their core competencies while divesting non-core assets to better-positioned partners.<\/p>\n\n\n\n<p>For Lepu, the acquisition represents a strategic expansion from medical devices into pharmaceutical solutions, creating opportunities for integrated cardiovascular care offerings that combine diagnostic, interventional, and therapeutic components.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding commercial performance, revenue projections, and market opportunities for Betagrin. Actual results may differ due to risks including market adoption rates, competitive pressures, pricing dynamics, and regulatory compliance requirements in China&#8217;s cardiovascular therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it&#8230;<\/p>\n","protected":false},"author":1,"featured_media":63229,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[289,69,374,1055,864],"class_list":["post-63227","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bio-thera-solutions","tag-cvd","tag-lepu-medical-technology","tag-sha-688177","tag-she-300003"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company Bio-Thera Solutions Inc. (SHA: 688177) to acquire all rights, assets, and business related to Betagrin (batifiban), a recently approved antiplatelet therapy for acute coronary syndrome.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=63227\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal\" \/>\n<meta property=\"og:description\" content=\"Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company Bio-Thera Solutions Inc. (SHA: 688177) to acquire all rights, assets, and business related to Betagrin (batifiban), a recently approved antiplatelet therapy for acute coronary syndrome.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=63227\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-15T13:33:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T13:33:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1502.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal\",\"datePublished\":\"2026-04-15T13:33:21+00:00\",\"dateModified\":\"2026-04-15T13:33:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227\"},\"wordCount\":484,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1502.webp\",\"keywords\":[\"Bio-Thera Solutions\",\"CVD\",\"Lepu Medical Technology\",\"SHA: 688177\",\"SHE: 300003\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63227#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=63227\",\"name\":\"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1502.webp\",\"datePublished\":\"2026-04-15T13:33:21+00:00\",\"dateModified\":\"2026-04-15T13:33:22+00:00\",\"description\":\"Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company Bio-Thera Solutions Inc. (SHA: 688177) to acquire all rights, assets, and business related to Betagrin (batifiban), a recently approved antiplatelet therapy for acute coronary syndrome.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=63227\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1502.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1502.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=63227#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company Bio-Thera Solutions Inc. (SHA: 688177) to acquire all rights, assets, and business related to Betagrin (batifiban), a recently approved antiplatelet therapy for acute coronary syndrome.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=63227","og_locale":"en_US","og_type":"article","og_title":"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal","og_description":"Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company Bio-Thera Solutions Inc. (SHA: 688177) to acquire all rights, assets, and business related to Betagrin (batifiban), a recently approved antiplatelet therapy for acute coronary syndrome.","og_url":"https:\/\/flcube.com\/?p=63227","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-15T13:33:21+00:00","article_modified_time":"2026-04-15T13:33:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1502.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=63227#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=63227"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal","datePublished":"2026-04-15T13:33:21+00:00","dateModified":"2026-04-15T13:33:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=63227"},"wordCount":484,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=63227#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1502.webp","keywords":["Bio-Thera Solutions","CVD","Lepu Medical Technology","SHA: 688177","SHE: 300003"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=63227#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=63227","url":"https:\/\/flcube.com\/?p=63227","name":"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=63227#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=63227#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1502.webp","datePublished":"2026-04-15T13:33:21+00:00","dateModified":"2026-04-15T13:33:22+00:00","description":"Lepu Medical Technology (SHE: 300003), a leading Chinese provider of cardiovascular disease solutions, announced it has signed a comprehensive licensing agreement with domestic biopharmaceutical company Bio-Thera Solutions Inc. (SHA: 688177) to acquire all rights, assets, and business related to Betagrin (batifiban), a recently approved antiplatelet therapy for acute coronary syndrome.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=63227#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=63227"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=63227#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1502.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1502.webp","width":1080,"height":608,"caption":"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=63227#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lepu Medical Acquires Betagrin Rights from Bio-Thera in RMB 450 Million Cardiovascular Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1502.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=63227"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63227\/revisions"}],"predecessor-version":[{"id":63230,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/63227\/revisions\/63230"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/63229"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=63227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=63227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=63227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}